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The development ofendotoxin toleranceby daily administration ofnonlethal doses
of endotoxin is well described in humans and experimental animals (1) . Tolerance
canbe induced to the lethal (2), metabolic (3), andpyrogenic (4) effects of endotoxin .
Themechanism of endotoxin tolerance is unclear, but recent studies suggest aprom-
inent role of modulation of macrophage function. Macrophages from endotoxin
tolerant animals exhibit a decreased production of prostaglandins (5) as well as de-
creased production of lipoprotein-lipase suppressor activity (6).
Anotherrecent series ofinvestigations has convincingly demonstrated that TNF,
a monokine secreted by macrophages in response to endotoxin and other stimuli,
plays a prominent role in the toxic and lethal effects of septicemia and endotoxin
(7-10) . Intravenous administration of human rTNF to rats (8) and dogs (9) simu-
lates the hemodynamic, metabolic, andhormonal derangements ofseptic shock . Passive
immunization of mice with polyvalent antiTNF antibodies before administration
ofalethal dose ofendotoxin significantly improves survival (10), andtreatment with
mAbs to TNF in baboons prevents death from a lethal injection of bacteria (11) .
Our laboratory (12) and others (13) have noted tolerance to the anorectic effects
of TNF with repetitive administration . Because of the prominent role ofTNF in
endotoxin toxicity and the suggestion oftolerance to repeated doses ofTNF similar
to endotoxin tolerance, we evaluated thephenomenon ofTNF tolerance in rats and
the interrelationship between endotoxin and TNF tolerance.
Materials and Methods
Animals.
￿
Male Fischer 344 rats (150-200 g) were individually housed in a light- and
humidity-controlled environmentwith a 12-h light/dark cycle . All rats were fed C-21 (ICN
Pharmaceuticals Inc., Cleveland, OH), a casein-based semi-synthetic diet that is non-scatterable
and allows accurate measurement of food intake (14).
Reagents.
￿
Human rTNF wasthe generous gift of theCetus Corp., Emeryville, CA, and
had a sp act of 10' U/mg as measured in the L929 bioassay and an endotoxin level of 30
pg/2.5 x 106U as measured by a standard limulus assay (15) . TNF was reconstituted with
PBS/0.5% BSA immediately before administration to rats in all experiments . LPS (Esche-
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richia coli 0127:R8 ; Sigma Chemical Co., St . Louis, MO) was reconstituted with sterile normal
saline on the day of use . In neutralizing antibody experiments, a highly purified preparation
of polyvalent rabbit anti-recombinant human TNF IgG antibody (Endogen, Boston, MA)
was used .
Nitrogen Balance Studies.
￿
In nitrogen balance studies, the rats were housed individually
in metabolic cages allowing daily collection of both urine and stool. Urine was collected in
a container with 1 ml of concentrated sulphuric acid . Urine nitrogen was quantitated by
chemoluminescence (Antek Instruments Inc ., Houston, TX). Aliquots of stool were ana-
lyzed in a similar fashion. Nitrogen intake was calculated from the daily food intake of C-21,
which has a known nitrogen content of 40.6 mg nitrogen per g C-21 .
ELISAforAntiTNFAntibodies .
￿
HumanrTNF was diluted to 10 Wg/ml in 0.05M sodium
carbonate buffer, pH 9.6, and 100 Wl/well was plated on 96-well Immulon microelisa plates
(Dynatech Laboratories, Inc ., Alexandria, VA) and kept at 4°C for 16 h . The plates were
washed three times with PBS/0.05% Tween-20 and blocked for 60 min with PBS/1%
BSA/0.05% Tween-20 blocking solution. The plates were washed, and 200 WI of serial dilu-
tions of rat sera was added for 120 min . Each sample was assayed in triplicate. The plates
were washed again, and 200 Wl of a 1 :1,000 dilution of goat anti-rat IgG alkaline phospha-
tase (Sigma Chemical Co.) or a 1 :800 dilution of sheep anti-rat IgM alkaline phosphatase
(Serotic, Indianapolis, IN) was added to each well for 120 min . The plates were washed, and
175 Wl of 1 mg/ml ofp-nitrophenyl phosphate (Sigma Chemical Co.) was added . After 45
min, the reaction was stopped with 50 Wl of 3 M NaOH . The plates were counted at 405
nm in a microelisa reader (Dynatech Laboratories, Inc.) . Sera from rats immunized by in-
tradermal injections ofTNF in Freund's complete adjuvant were analyzed in each assay as
positive controls .
L929 TNFBioassay
￿
A standard cytotoxicity assay forTNF activity using aTNFsensitive
L929 cell line was performed (16) . Briefly, 100 Wl of 2.5 x 10 5 cells/ml suspension of L929
cells in RPMI/10% FCS complete media was plated on 96-well plates (Costar Data Pack-
aging Corp ., Cambridge, MA) and cultured overnight to establish a monolayer. On parallel
plates, serial dilution of sera samples were made in complete media with 1.5 Wg/ml actinomy-
cin-D (Merck Sharpe &Dohme, West Point, PA) and 100 WI of this solution was transferred
to plates with the L929 cells giving a final concentration of 0.75 Wg/ml of actinomycin-D .
After 18 h, the surviving cells were fixed, stained with 0.5% crystal violet (Sigma Chemical
Co.), and the plates were counted in a titertek at 590 run . 1 U of activity was defined as the
reciprocal of the dilution required to produce a50% decrease in absorbance relative to con-
trol cells exposed to actinomycin alone . Each sample was assayed in triplicate . In assays using
a neutralizing antibody, samples were mixed with a 1 :1 vol ofa 1 :100 dilution ofpolyvalent
anti-humanTNF antibody for 2 h at 4°C before analysis in the L929 bioassay. These assays
were performed in parallel with samples treated with control nonimmune rabbit serum
(Endogen) .
Pathology.
￿
In pathologic studies, rats were anesthetized with intraperitoneal pentobarbital,
and a segment ofsmall intestine immediately proximal to the cecum and the liver was quickly
excised and placed in 10% formaldehyde. The lungs were then excised and irrigated gently
by tracheal cannulation with 5 ml of 10% formaldehyde and then placed in a vial with 10%
formaldehyde . Standard hematoxylin and eosin slides were prepared (American Histo Labs,
Rockville, MD), and the slides were read in the blinded fashion by a pathologist(M. J . Merino) .
Statistics.
￿
Data are presented asmean t SEM unless otherwise stated . Parametric results
are analyzed by independent student's t test and nonparametric by Wilcoxon rank sum test .
Survival comparisons are made by Fisher's exact test.
Results
The metabolic and nutritional effects of repeated doses of TNF were evaluated
in Fischer 344 rats. Human rTNF administered twice daily intraperitoneally at a
dose of 100 gg/kg led to a decrease in daily food intake from 11.5 to 3.7 g (a 68
decrease), a decrease in daily body weight change from 4.6 to -6.0 g per day (Fig.FRAKER ET AL .
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FIGURE 1.
￿
Fischer 344 rats (150-175 g) were in-
dividually housed and fed a diet of C-21. After
a period of standardization of food intake and
body weight, rats were randomized to receive ei-
ther twice daily intraperitoneal carrier buffer (n
= 20) or TNF twice daily at adose of 25 pg/kg
(n = 18) or 100 pg/kg (n = 17) . The treatment
period was5 consecutive days . Daily food intake
(A) andbody weightchange (B) were measured .
Data are mean t SE .
1, A and B), and negative daily nitrogen balance from 221 mg/d to -24 mg/d (Table
I) . However, continued twice daily administration ofTNF at the same dose led to
a reversal of these nutritional alterations . By the third day of treatment, the food
intake doubled from 3.7 to 7.0 g, and the daily nitrogen balanceand the daily change
in body weight became positive at 96 mg of nitrogen per day and 4.4 g per day,
respectively, despite continued TNF administration . Further treatment with TNF
at the same dose led to continued recovery offood intakeand nitrogen balance (Fig . 1
and Table I) .
The initial alterations in food intake and body weight change were dose depen-
dent, and the rate of recovery was also proportional to the dose ofTNF administered .
For example, at low-doseTNF (25 lxg/kg twice daily) food intake decreased to 5.4 g
during the first day, but increased to 8.2 g during the second day (a 50% recovery) .
In the high-dose TNF (100 gg/kg twice daily) group, food intake for the first 2 d
was 3.7 and 4.7 g (a 27% recovery) . Similarly body weight change in the low-dose
group dropped initially to a loss of 2.2 g for the first day, but recovered to control
levels of a 4.4 g per day gain in weight by the second day. In the high-dose group,
the rats were still losing weight at -0.6 g per day during the second day. A tolerant
state in terms of food intake andbody weight change (defined as levels not different
from control rats) was reached by 2-3 d of treatment in the low-dose group, but
was not reached at 5 d of treatment in high-dose TNF group (Fig . 1).98
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TABLE I
Nitrogen Balance in Rats Treated with TNFfor
5 Consecutive Days vs. Control
10 growing male Fischer 344 rats (150-175 g) were housed individually in meta-
bolic cages. TheTNFgroup received humanTNF (100 pg/kg, i.p.) twice daily
(n = 5), while control rats had saline injections (n = 5). Animals were fed
aC-21 diet. Urines were collected andanalyzed as described in Materials and
Methods. Nitrogen balance wasrecorded as nitrogen in from food intake mi-
nusnitrogen excreted in urine. Stool nitrogen wasdetermined in selected rats
andfound to contribute <5% to total daily nitrogen loss and was not includ-
ed in the calculations.
p < 0.05 vs. control.
t p < 0.05 vs. TNF during days 1 and 2.
This observed tolerance to the anorectic effects ofhuman TNF in rats also pro-
tected theseanimalsagainsta subsequentchallengewith alethal dose ofintravenous
TNF (Table II). Rats receiving twice daily TNF at the high dose of 100 Ag/kg for
5d had a 100% survivalwhen challenged 2 d laterwith anintravenous dose ofTNF
that killed 50% of control rats (p < 0.05). Tolerance to TNF toxicity also protected
rats from a lethal dose ofendotoxin. Rats pretreated with high-dose TNF had an
88% survival when challenged 2 dlater with intravenous endotoxin compared with
TABLE II
Survival in TNF or Endotoxin-tolerant Rats Challenged with
Intravenous TNF or Endotoxin
Rats were tolerized to TNF by twice daily intraperitoneal injections of 100
pg/kg TNF for 5 consecutive days. Rats were tolerized to LPS by daily injec-
tion of1 mg/kg LPSfor 4consecutive days. Control rats in each group received
twice daily injections of carrier buffer. Rats were challenged with either 10
mg/kg LPS or 200 pg/kg TNF i.v. by tail vein injection 2 d after the final
tolerization day. Survival was followed for 72 h.
p < 0.05 vs. control/TNF challenge.
t p < 0.01 vs. control/LPS challenge.
Day-of TNF
treatment Control
Nitrogen balance (N/day)
Cachectin
mg
1 213 t 60 - 23 t 26"
2 206 t 34 -26 t 21
3 319 t 32 96 t 30"
4 256 t 32 150 t 36'
5 273 t 31 207 t 20t
Tolerizing
agent
Challenge
agent
72-h
survival
Control (saline) TNF 4/8 (50)
TNF TNF 8/8 (100)'
LPS TNF 9/9 (100)'
Control (saline) LPS 1/16(6)
TNF LPS 14/16 (88)t
LPS LPS 10/10 (100)$FRAKER ET AL .
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TABLE III
Determination of Dose Effect, Length of Toleriwtion, and Duration of
Tolerance Effect in TNF-tolerant Rats Challenged with
Intraperitoneal Endotoxin
The two treatment groups received human TNF at doses of 25 pg/kg or 100 Pg/kg i.p. twice
daily for the number of days indicated in the left hand column . Thecontrol group received
an injection of buffer intraperitoneally twice daily . Daily food intake and body weight were
measured throughout theexperiment to document tolerance . At the day indicated in the ta-
ble (with day 1 being the first day ofTNF treatment), rats received a single LD5o dose of
5 mg/kg endotoxin i.p . Survival is reported at 72 h after endotoxin challenge .
' p < 0.005 vs . control .
t p < 0.01 vs . 25 pg/kg dose .
a 6% survival in control rats challenged with the same endotoxin dose (p < 0.01) .
The interrelationship betweenTNFand endotoxin tolerance was further supported
by the observation that endotoxin-tolerant animals are also protected against an
LD5o dose of TNF (100% survival vs . 50% survival, p < 0.05) (Table II) .
Characteristics of the TNFinduced endotoxin tolerant state were examined by
varying the duration ofTNF pretreatment, the dose ofTNF used, and the timing
ofsubsequent endotoxin challenge (Table III). TNFinduced tolerization to endotoxin
is dose dependent as low-dose (25 fag/kg) twice daily TNF injections failed to pro-
vide protection against an LD5o dose of endotoxin in two different tolerization reg-
imens in which a dose of 100 Wg/kg was efficacious . A tolerization time period of
3 d of twice daily 100 pg/kg injections was able to protect rats against a lethal dose
of endotoxin given 2 d later. Duration ofTNFinduced tolerance to endotoxin was
limited. Rats were protected against endotoxin challenge 2 d (Table II and III) and
4d (Table III) after the last day ofTNF tolerization, but the protective effects were
not seen at 16d after tolerization . In the latter instance, survival to endotoxin chal-
lenge was equal in both TNFpretreated and control groups (Table III) .
The protective effects o£ high-dose TNF pretreatment or TNF tolerance on sur-
vival to lethal doses of endotoxin also translated to clear improvement of histopatho-
logic alterations ofendotoxemia. The histologic changes present in control animals
8 h after high-dose endotoxin are partially or completely reversed in rats that were
tolerant toTNF The severe pneumonitis and edema in the lungs (Fig . 2, a and b),
the hepatic necrosis (Fig . 2, c and d), and the ischemic necrosis of the small bowel
(Fig . 2, e andf) are all improved dramatically in TNFpretreated rats . Normaliza-
tion of the severe histopathologic changes that occur after a single lethal dose ofTNF
to control animals were also observed in rats who were tolerant to TNF (data not
shown).
One possible explanation for the mechanism ofTNF tolerance is that it is an ar-
tifact of alterations in the pharmacokinetics of TNF after the multiple injections
Days of
TNF
treatment
Day of
endotoxin
challenge Control
72-h survival
25 pg/kg
TNF
100 pg/kg
° fo
3 5 22/50(44) 6/10(60) 34/40(85)'
5 9 6/18(33) 3/9 (33) 9/9 (100)'t
5 21 10/16(62) 7/9 (78) 5/8 (62)100 -
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FIGURE 2 .
￿
Photomicrographs ofH & E slides from specimens of a rat made tolerant to TNF
(b, 4 and.Í) by twicedaily 100 Wg/kg i.p . injection ofTNF ora control rat (a, c, and e). Specimens
were obtained as described in the text 8 h after intravenous injection of 10 mg/kgofendotoxin .
Lungcontrol (x 65) (a), TNF tolerant (b) ; liver control (x 80) (c), TNF tolerant (d) ; ileum control
(x 35) (e) and TNF tolerant (f).
during the tolerizing period . Repeated intraperitonealinjections ofTNF might alter
theabsorption ofsubsequent intraperitoneal administration ofTNF, or it might alter
clearance or degradation of intravenously injected TNF To evaluate these hypoth-
eses, circulatingTNF activity was assayed in TNFtolerant and control rats . The
level ofTNF activity in the sera afterintraperitoneal injection of 2001<g/kg ofTNFin TNFtolerantrats was not significantlydifferentfromthe levelin control rats(Fig.
3). Also, peak levels and clearance after intravenous injection of200 gg/kg ofTNF
were not different between the two groups (Fig. 4). In both experiments, there was
no residualcirculating TNF activity inthe TNFpretreated groups attime zero, be-
fore the injection of 200 gg/kg of TNF. Parallel assays with the sample pretreated
with a neutralizing antibody to humanTNF at a 1:200 dilution eliminated allmea-
surable activity (levels <10 pg/ml in the presence ofthe neutralizing antibody, data
not shown) at everydatapointinboth tolerant and control animals, confirmingthat
the bioassays were measuring the injected human rTNF.
In another group ofrats, the magnitude andtime course ofthe humoral immune
response totheintraperitonealTNF tolerization regimenwasevaluated. Rats toler-
ized to TNF at 100 gg/kg, twice daily for 5 d, had blood drawn on day 9 or 4 d
afterthe last tolerization dose. A second group ofrats tolerized in a similar manner
had blood drawn on day 21 or 16 d after the last tolerization dose. Rats treated in
this manner were shown to be refractory to a lethal dose of TNF at day 9 but not
at day 21 (Table III). Titers of circulating anti-human TNF IgM and IgG anti-
bodies were measured. At day 9, there was essentially no measurable circulating
IgG orIgM to humanTNF (Table IV). Byday 21, low titers ofIgG antibodieswere
present, but dilutions of only 1:25 gave <1/2 maximal absorbance in the ELISA.
FRAKER ET AL.
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FIGURE 3.
￿
TNF tolerant rats (n = 6) were treated
twice daily TNF at 100 pg/kg i.p. for 5 d, Control
rats (n = 6) received saline injections. 1 dafter the
tolerization period, allrats received 200pg/kgTNF
i.p. Serial blood samples were assayed for TNF ac-
tivity in theL929 bioassay at thetimesshown. Astan-
dard curve usingrTNF was run with each assay to
convert U/ml to ng/ml. Data aregiven as mean t
SE. There areno differences in TNFlevels between
TNFtolerant and control rats at any time point.
FIGURE 4.
￿
TNFtolerant rats andcontrol rats were
treated identicalto the experiment in Fig. 3 except
the200 pg/kgdose ofTNFwasgiven intravenously.
TheTNFactivity wasdetermined by theL929 bio-
assay. n - 6 in both groups. Data are as mean t
SE. Thereareno differences in TNFlevels between
TNFtolerant and control rats at any time point.102
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TABLE IV
Levels of IgM or IgG Rat Anti-human TNF Antibodies after
Toleriaation of Rats to TNF
OD
F344 rats were tolerized to TNF by twice daily intraperitoneal injections of 100 pg/kg TNF
for 5 consecutive days (days 1-5). On days 9 and 21, blood was obtained by retro-orbital
puncture, and sera were assayed for anti-TNF antibodies. The data shown are the mean
absorbance t SE for the ELISA as described in Materials and Methods. n = 10 for each
group.
p < 0.05 vs. control.
Rats immunized with TNF in FCAandboosted three times withTNF in IFA were
used as a positive control for all ELISA. Titers of >1 :12,400 were present in these
immunized rats. Therefore, human rTNF is antigenic for rats, but administration
by repeated intraperitoneal injections provokes only a minimal response. The pres-
ence oflow levels of anti-human TNF antibodies does not correlate with the TNF
tolerant-induced resistance to a lethal dose of endotoxin.
Discussion
Repeated intraperitoneal administration oftwice daily nonlethal doses ofrecom-
binant human cachectin/TNF for 3-5 d to rats makes these animals refractory to
theusual toxic effectsofthismonokine. The initial alteration ofnutritionalparameters
including food intake, body weight change, and nitrogen balance all normalize de-
spite continued administration of the same dose ofTNF . Similarly, the lethality of
TNF is abrogated by TNF pretreatment with nonlethal doses. This TNFtolerant
condition also clearly translates into protection against the toxicity and lethality of
endotoxin. TNFinduced tolerance to endotoxin can develop with only 3 d ofTNF
pretreatment, is dependent upon the dose ofTNF used, and is present for at least
2-4 d after pretreatment, but dissipates by 2 wk.
The mechanism ofthis TNF tolerance is unclear. One explanation for the early
recovery ofnutritional parameters isthatrepetitive intraperitoneal injections ofTNF
alters absorbance ofsubsequent dosesso thatthe actual delivereddose ofTNFdecreases
during the tolerization period. However, as can be seen in Fig. 3, the blood levels
ofTNF activity after 200 gg/kg ofTNF are equivalent in TNRtolerant and control
animals. Also, thetolerant stateisnot dueto rapid clearance or degradation ofTNF
as the peak bioactivity in tolerant rats is not lower nor is the TNF cleared faster
than in control rats after injection ofthe same intravenous dose (Fig. 4). Therefore,
the TNFtolerant animals demonstrate no toxicity to TNF despite equivalent levels
of circulating TNF bioactivity.
Anotherpossiblemechanism forTNFtolerizationisahumoralimmuneresponse.
Passive immunization with antiTNF antibodies has been shown to be protective
againstendogenous TNFin endotoxemia(10) andbacteremia (11). However, several
factors argue against the tolerance phenomenon described in the present study as
Day
of
sample
Antibody
class
TNF
1 :25
tolerant
1 :100 1 :25
Control
1 :100
9 IgM 0.11 t 0.06 0.05 t 0.02 0.06 t 0.06 0.03 t 0.02
9 IgG 0.06 t 0.01 0.07 t 0.01 0.05 t 0.02 0.07 t 0.02
21 IgG 0.85 t 0.66` 0.57 t 0.76" 0.10 t 0.01 0.04 t 0.01MAKER ET AL.
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an active immunization of rats to THE First, the time course of the response with
improved nutritional parameters by 2 d is much faster than would be expected for
a primary immune response. Second, levels of circulating antiTNF antibodies are
unmeasurable at the time when rat's are TNF tolerant, and are present at low titers
when the TNF tolerance has dissipated(Table IV). Finally, the effects ofTNF across
species barriers (17), and particularly the ability ofantiTNF antibodies to recognize
xenogenic TNF, is low (18), so that antibodies to injected human TNF may afford
minimal protection against endogenous rat THE
Therefore, the mechanism of TNF tolerance does not appear to be an artifact
ofTNF delivery or a primary humoral immune response. Possible alternative expla-
nations include down regulation of number or affinity of specific cell surface receptors
that are known to be present on a variety of normal cells (19) that may be direct
targets of TNF toxicity. Also, the cellular immune responses to TNF may be altered
to a refractory condition by repeated TNF stimulation.
The relationship of TNF tolerance to the well-described phenomenon ofendotoxin
tolerance is a new observation, and its mechanism is not clearly defined. In the rat,
the endotoxin-tolerant condition protects against a lethal TNF challenge as well as
a lethal endotoxin challenge, and similarly a TNFtolerant condition protects against
both TNF and endotoxin. The mechanism of endotoxin tolerance is thought to in-
volve a decreased responsiveness of host macrophages to endotoxin stimuli [1, 5] .
As macrophages express specific TNF receptors (20) and are thought to be the pre-
dominant source of endogenous TNF (7), modulation of macrophage activity may
explain both endotoxin,and TNF tolerance. However, the hypothesis that endotoxin-
tolerant macrophages are functionally depleted in terms of monokine secretion and
other responses to stimuli does not explain why endotoxin-tolerant rats are resistant
to a lethal dose of TNF unless TNF toxicity is mediated primarily by a secondary
response via the macrophages.
TNF tolerance may have relevance to two areas of clinical medicine. It is well rec-
ognized that TNF produces a wide range of effects on several different cell types
(7, 21), but when present in excess amounts in endotoxemia or bacteremia, it clearly
leads to severe toxicity and death (10, 11). Also, TNF may play a role in the patho-
genesis of cancer cachexia (22). Therefore, any mechanism to modulate the toxic
effects ofTNF, such as induction of tolerance, may potentially improve survival and
outcome in both sepsis and cancer cachexia. Another clinically relevant application
of TNF tolerance is in the potential use of TNF as an anti-neoplastic agent. In an-
imal studies, TNF has had profound anti-tumor effects in animal models (23), and
several centers have administered rTNF as an experimental therapeutic agent to tumors
often involving multiple dosing schedules (24). Ifthe tolerance phenomenon observed
in rats also occurs in humans, a full understanding of the kinetics and degree of
tolerance may alter dosing schedules to optimize therapeutic efficacy and minimize
toxicity. Further studies are necessary to find the precise mechanism of TNF toler-
ance and to define the application of TNF tolerance to sepsis, cancer cachexia, and
anti-neoplastic treatment.
Summary
Treatment of rats with recombinant human TNF initially causes a marked de-
crease in food intake, a loss of body weight, and a negative nitrogen balance. These
alterations normalize with continued twicedaily intraperitoneal injections ofthe same104
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dose. Rats tolerized to TNF in this manner are refractory to a lethal dose of TNF .
Also, TNFpretreated and -tolerized rats have prolonged survival and reversed his-
topathologic changes after injection of a lethal dose ofendotoxin compared with control
animals. The TNFtolerant state is dependent on the dose of TNF used and the
length of TNF pretreatment. TNFinduced tolerance is relatively shortlived, being
present 2-4 d after TNF pretreatment and dissipating by 2 wk. Rats made tolerant
to endotoxin are also tolerant to a lethal dose ofTHE A bidirectional crossreacting
tolerance exists between TNF and endotoxin. The mechanism of TNF tolerance
is unclear, but it does not appear to be due to a humoral immune response or a
perturbation of the uptake and clearance of injected TNF.
Receivedfor publication 2 March 1988.
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